A 35-year-old man with a known history of Graves' disease, currently on propranolol monotherapy, presents with palpitations, tremor, and heat intolerance for 2 weeks. His thyroid is diffusely enlarged and tender. On examination: HR 110 bpm, BP 145/85 mmHg, fine tremor, warm moist skin. Laboratory results: TSH <0.01 mIU/L (suppressed), free T4 6.2 ng/dL (normal 0.8–1.8), free T3 8.5 pg/mL (normal 2.3–4.2), TSI (TSH receptor antibodies) strongly positive. He reports poor compliance with antithyroid medications. What is the most appropriate next step in management?

Explanation

## Clinical Diagnosis This patient has **uncontrolled Graves' disease (primary hyperthyroidism)** with: - Markedly elevated free T4 and T3 - Suppressed TSH - Strongly positive TSI (TSH receptor antibodies) - Clinical signs of thyrotoxicosis (palpitations, tremor, heat intolerance, tachycardia, hypertension) - Poor compliance with antithyroid drugs ## Management Approach for Graves' Disease ```mermaid flowchart TD A[Graves' disease confirmed<br/>TSH suppressed, elevated T4/T3, TSI+]:::outcome --> B{Acute thyrotoxicosis?}:::decision B -->|Yes, severe| C[Beta-blocker + antithyroid drug<br/>+ iodine for crisis]:::action B -->|No, moderate| D[Beta-blocker + antithyroid drug<br/>Methimazole or PTU]:::action D --> E[Monitor TSH, free T4 at 4–6 weeks]:::action E --> F{Euthyroid?}:::decision F -->|Yes| G[Continue antithyroid<br/>Consider definitive therapy]:::action F -->|No| H[Adjust antithyroid dose]:::action C --> I[Once euthyroid:<br/>Consider thyroidectomy or RAI]:::action ``` ## Key Point: **The standard initial management of Graves' disease is a combination of:** 1. **Beta-blocker** (propranolol) — controls adrenergic symptoms (palpitations, tremor, anxiety) 2. **Antithyroid drug** (methimazole or PTU) — inhibits thyroid hormone synthesis 3. **Iodine** (Lugol's or SSKI) — only if thyroid storm or severe thyrotoxicosis; blocks hormone release and reduces gland vascularity **High-Yield:** Methimazole is preferred over PTU in non-pregnant patients because: - Once-daily dosing (better compliance) - Faster onset of action - Lower risk of hepatotoxicity - PTU reserved for first trimester pregnancy or methimazole intolerance ## Rationale for Correct Answer This patient is **not in thyroid storm** (no fever, altered mental status, or severe hemodynamic instability), so iodine is not the immediate first step. The next step is: 1. **Increase propranolol** to 160 mg/day (or equivalent) to control adrenergic symptoms 2. **Add methimazole 30 mg/day** (starting dose: 10–30 mg/day; higher doses for severe hyperthyroidism) 3. **Monitor TSH and free T4 at 4–6 weeks** to assess response and adjust antithyroid dose Once euthyroid, the patient can be counseled about **definitive therapy** (radioactive iodine or thyroidectomy). ## Clinical Pearl: Propranolol has a dual advantage in Graves' disease: - Blocks beta-adrenergic effects of excess thyroid hormone - **Inhibits peripheral conversion of T4 → T3** (the more potent form), providing additional benefit Other beta-blockers (atenolol, metoprolol) do NOT have this conversion-blocking effect. ## Antithyroid Drug Dosing and Monitoring | Parameter | Methimazole | PTU | |-----------|-------------|-----| | Starting dose | 10–30 mg/day | 50–100 mg/day | | Frequency | Once or twice daily | Three times daily | | Onset | 1–2 weeks | 1–2 weeks | | Hepatotoxicity risk | Low (rare) | Higher (0.1–0.2%) | | Agranulocytosis | ~0.3% | ~0.2% | | Preferred in pregnancy | No (teratogenic) | Yes (first trimester) | | Preferred in non-pregnant | Yes | No | ## Monitoring Schedule - **4–6 weeks:** TSH, free T4 (assess response, adjust antithyroid dose) - **Monthly:** CBC (check for agranulocytosis if symptomatic) - **Every 3 months:** TSH, free T4 once stable - **Counsel patient:** Report fever, sore throat, rash (signs of agranulocytosis or drug reaction)